Deep Learning Assisted Epithelial Basement Membrane Dystrophy Detection

March 13, 2023 updated by: Prim. Prof. Dr. Oliver Findl, MBA, Vienna Institute for Research in Ocular Surgery

Automated Deep Learning for Detection of Epithelial Basement Membrane Dystrophy Using Optical Coherence Tomography and Longitudinal Reproducibility of Disease Characteristics

Epithelial basement membrane dystrophy, also known as Map-Dot fingerprint dystrophy or Cogan microcystic dystrophy, is a common bilateral dystrophy of the anterior human cornea. According to one study, it affects approximately 2% of the human population. A more recent study even reported basement membrane changes in 25% of the general population. However, due to its clinical and morphological appearance, the disease is probably often overlooked.

Although epithelial basement membrane dystrophy is asymptomatic in many affected patients, there are some important clinical consequences of the disease to consider: Dystrophy is estimated to be the second most common cause of recurrent corneal erosion syndrome and is also an important differential diagnosis of dry eye disease. Therefore, it can cause severe pain in affected patients. In addition, epithelial basement membrane dystrophy plays an important role in the context of cataract surgery, one of the most commonly performed surgeries worldwide: besides the importance of appropriate disease management before surgery to prevent postoperative exacerbation of ocular surface symptoms, epithelial basement membrane dystrophy is also a risk factor for inaccurate preoperative biometry.

In recent years, specific features of epithelial basement membrane dystrophy have been introduced in examination methods other than slit-lamp biomicroscopy, such as epithelial thickness mapping or optical coherence tomography. Due to the recent introduction of a variety of deep learning systems, the application of machine learning could significantly increase the detection rate for epithelial basement membrane dystrophy. Furthermore, to the best of our knowledge, the change in disease characteristics over time is currently unknown.

Therefore, the first part of this study will investigate the ability of an automated deep learning system using optical coherence tomography scans to distinguish between normal human corneas and corneas affected by epithelial basement membrane dystrophy. For this purpose, 100 eyes of 50 patients will be included in both study groups. In an optional 2nd part of the study, a second visit will be planned in patients with epithelial basement membrane dystrophy to investigate the reproducibility of disease characteristics as a secondary outcome.

Study Overview

Detailed Description

This study aims to investigate the capability of an automated deep learning system using anterior segment optical coherence tomography scans to distinguish between normal human corneas and corneas affected by epithelial basement membrane dystrophy. In an optional substudy, a second visit will be scheduled to investigate the reproducibility of disease characteristics as a secondary outcome.

One-hundred eyes of 50 patients with epithelial basement membrane dystrophy and 100 eyes of 50 healthy subjects will be included in this study. After successful screening, all study participants will undergo one single study visit. During this visit, two questionnaires (Ocular Surface Disease Index, Quality of Vision), two different anterior segment optical coherence tomography devices (MS-39, Anterion), a slit lamp examination including slit lamp photography will be performed.

In an optional substudy, patients with epithelial basement membrane dystrophy will have a second visit, to compare the variability of disease characteristics, including number of maps, dots, fingerprint lines and cysts between the two visits.

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Oliver Findl, MD, MBA, FEBO
  • Phone Number: +43 1 91021- 57564
  • Email: office@viros.at

Study Locations

      • Vienna, Austria, 1140
        • Recruiting
        • Vienna Institute for Research in Ocular Surgery (VIROS)
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Community sample

Description

Inclusion Criteria (Group 1):

  • Age 18 or older
  • Written informed consent
  • Presence of epithelial basement membrane dystrophy

Inclusion Criteria (Group 2):

  • Age 18 or older
  • Written informed consent
  • No corneal pathology in both eyes

Exclusion Criteria:

  • Other corneal conditions (such as corneal scarring, fuchs endothelial corneal dystrophy, etc.)
  • Pregnancy (pregnancy test will be taken in women of reproductive age), nursing women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Epithelial Basement Membrane Dystrophy
Patients with epithelial basement membrane dystrophy
Two different optical systems (MS-39, Costruzione Strumenti Oftalmici Italy; Anterion optical coherence tomographer, Heidelberg Engineering) will be used for acquisition of cross-sectional scans. Radial scan patterns will be used for acquisition.
Healthy
Patients/Subjects without corneal pathologies
Two different optical systems (MS-39, Costruzione Strumenti Oftalmici Italy; Anterion optical coherence tomographer, Heidelberg Engineering) will be used for acquisition of cross-sectional scans. Radial scan patterns will be used for acquisition.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Sensitivity of the deep learning system to detect optical coherence tomography scans with epithelial basement membrane dystrophy on the final test data set
Time Frame: 1 day
1 day
Specificity of the deep learning system to detect optical coherence tomography scans with epithelial basement membrane dystrophy on the final test data set
Time Frame: 1 day
1 day
Area under the curve of the deep learning algorithm on the final test data set
Time Frame: 1 day
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Interobserver variability regarding disease diagnosis (normal cornea vs. epithelial basement membrane dystrophy) according to slit lamp photographies
Time Frame: 1 day
1 day
Interobserver variability regarding number of maps according to slit lamp photographies
Time Frame: 1 day
1 day
Interobserver variability regarding number of dots according to slit lamp photographies
Time Frame: 1 day
1 day
Interobserver variability regarding number of fingerprints according to slit lamp photographies
Time Frame: 1 day
1 day
Interobserver variability regarding number of cysts according to slit lamp photographies
Time Frame: 1 day
1 day
Difference in epithelial thickness mapping between healthy corneas and corneas affected by epithelial basement membrane dystrophy
Time Frame: 1 day
1 day
Difference in Ocular Surface Disease Index between healthy subjects and patients affected by epithelial basement membrane dystrophy
Time Frame: 1 day
minimum: 0, maximum: 100, higher scores are associated with increased symptoms regarding ocular surface disease
1 day
Difference in Quality of Vision questionnaire score between healthy subjects and patients affected by epithelial basement membrane dystrophy
Time Frame: 1 day
0- to 100-unit linear scale, higher scores indicating poorer quality of vision
1 day
Sub-study only: Reproducibility of number of maps between visit 1 and visit 2 according to slit lamp photographies and optical coherence tomography images
Time Frame: 3 months
number of corneal maps will be assessed by a clinical investigator at both visits
3 months
Sub-study only: Reproducibility of number of dots between visit 1 and visit 2 according to slit lamp photographies and optical coherence tomography images
Time Frame: 3 months
number of corneal dots will be assessed by a clinical investigator at both visits
3 months
Sub-study only: Reproducibility of number of fingerprints between visit 1 and visit 2 according to slit lamp photographies and optical coherence tomography images
Time Frame: 3 months
number of corneal fingerprint lines will be assessed by a clinical investigator at both visits
3 months
Sub-study only: Reproducibility of number of cysts between visit 1 and visit 2 according to slit lamp photographies and optical coherence tomography images
Time Frame: 3 months
number of corneal cysts will be assessed by a clinical investigator at both visits
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 27, 2023

Primary Completion (Anticipated)

February 27, 2024

Study Completion (Anticipated)

February 27, 2024

Study Registration Dates

First Submitted

February 27, 2023

First Submitted That Met QC Criteria

March 13, 2023

First Posted (Actual)

March 15, 2023

Study Record Updates

Last Update Posted (Actual)

March 15, 2023

Last Update Submitted That Met QC Criteria

March 13, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Map Dot Fingerprint Dystrophy

Clinical Trials on anterior segment optical coherence tomography

Subscribe